LNAI.US Lunai Bioworks Inc.

Healthcare Biotechnology USA Stocks
0.1648 USD
Close of Nov 15, 2026
0.1470 5.02
Market cap
USD 830K
P/E
-
P/B
0.48x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is LNAI.US undervalued?

Graham number

The Graham number of Lunai Bioworks Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lunai Bioworks Inc. fundamental analysis

No fundamental analysis for Lunai Bioworks Inc. yet.

Lunai Bioworks Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lunai Bioworks Inc.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics p…

Full company profile